文献速递心律失常心力衰竭与心肌病血脂与心血管预防

早发心房颤动的基因检测:临床意义与实施挑战

Genetic testing in early-onset atrial fibrillation.
PubMed 文献 · Eur Heart J · 2024-01-01

本文综述早发心房颤动(AF)的遗传学基础与基因检测的临床价值。早发AF患者中罕见致病性变异检出率约4%-11%,以心肌病基因最为可干预;2023年ACC/AHA指南对≤45岁AF患者基因检测给出IIb类推荐。文章同时讨论意义未明变异(约60%)及实施障碍。

要点

  • 早发AF患者中罕见致病性变异检出率约4%-11%,以心肌病基因最具临床可操作性。
  • 2023年ACC/AHA指南对≤45岁AF患者基因检测给出IIb类推荐。
  • 约60%早发AF患者可能携带意义未明变异,需检测前后咨询与规范报告。

核心结论

  • 基因检测有助于识别早发AF患者中与单基因缺陷及遗传性心肌病相关的致病变异,可能改善预后与管理。
  • 将基因检测纳入早发AF诊疗可支持个体化筛查、级联检测及基因型指导的预后与预防,但需多方支持的框架保障。

研究设计与样本

  • 综述类文章,围绕早发AF的遗传学证据、基因检测推荐与实施挑战进行汇总。
  • 引用近期大规模遗传学研究及早发AF患者罕见致病变异检出数据。

主要发现

  • 早发AF患者中罕见致病性变异检出率约4%-11%。
  • AF与遗传性心室心肌病及心律失常综合征存在临床与遗传重叠,AF可为年轻个体严重心室病的早期指示。
  • 多达约60%的早发AF人群可能携带意义未明变异。
  • 现有遗传学证据主要基于欧洲血统人群。

关键数值与推荐

  • 2023年ACC/AHA房颤指南对≤45岁AF患者基因检测给出IIb类推荐。
  • 早发AF患者中罕见致病性变异检出率约4%-11%,以心肌病基因最为临床可干预。
  • 约60%的早发AF人群可能携带意义未明变异。

临床怎么用

  • 对≤45岁早发AF患者可考虑基因检测,以识别遗传性心肌病及心律失常综合征相关致病变异。
  • 检测前后应进行患者教育(含检测前咨询),并规范选择高置信度基因与报告。
  • 阳性结果可支持级联检测、更 tailored 的筛查及基因型指导的预后与预防。

局限性

  • 意义未明变异比例高(约60%),结果解读存在不确定性。
  • 实施面临经济障碍、可保险性问题、人力限制及标准化定义需求。
  • 现有遗传学证据主要来自欧洲血统人群,需多样化研究队列与国际合作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%-11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research-mechanistic, translational, and clinical-is urgently needed.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kany S, Jurgens SJ, Rämö JT, et al. Genetic testing in early-onset atrial fibrillation. Eur Heart J. 2024. PMID: 39028637. doi:10.1093/eurheartj/ehae298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。